Avricore Health Inc. is a pharmacy service innovator that acquires and develops early stage technologies to advance pharmacy practice. Its core offering is the HealthTab point of care testing platform which provides rapid blood analysis within twelve minutes at community pharmacy locations. The system uses a finger stick sample and can report up to twenty seven biomarkers related to heart liver and kidney function. The company has discontinued its over the counter generic…
Avricore Health Inc. is a pharmacy service innovator that acquires and develops early stage technologies to advance pharmacy practice. Its core offering is the HealthTab point of care testing platform which provides rapid blood analysis within twelve minutes at community pharmacy locations. The system uses a finger stick sample and can report up to twenty seven biomarkers related to heart liver and kidney function. The company has discontinued its over the counter generic drug business and concentrates solely on delivering diagnostic services through HealthTab.
Avricore Health Inc. generates revenue primarily from the sale lease or licensing of HealthTab analyzers and associated software services to pharmacy chains and independent pharmacists. For the year ended December 31 2024 revenue increased 37% year over year to $4,785,711 and gross profit increased 56% to $1,880,287. In the three months ended December 31 2024 revenue increased 5% year over year to $1,421,076 and gross profit increased 18% to $589,930. Revenue also arises from service agreements that provide ongoing support data management and connectivity to health records. The company’s customers are mainly retail pharmacy operators seeking to expand point of care testing capabilities.
Avricore Health Inc. occupies a niche within the point of care testing market by linking pharmacy based diagnostics with real time data transmission capabilities. The company differentiates itself through its cloud based network that delivers lab accurate results in twelve minutes and enables real world data collection for research partners. While competitors offer standalone analyzers Avricore’s integration with pharmacy workflows and its partnerships with organizations such as the Ontario Pharmacists Association give it a competitive advantage in securing pharmacy placements. The global point of care testing market is projected to reach 93.21 billion USD by 2030 underscoring the growth opportunity. Avricore has been recognized in the Pharmaceutical Journal following a BMJ report on point of care device standards highlighting its commitment to best practices. The company also collaborates with CROs labs pharmacies and researchers to generate real world data that can be shared with life science companies.
Avricore Health Inc. serves retail pharmacy chains and independent pharmacies across Canada and the United Kingdom. Specific customers include Shoppers Drug Mart Loblaw family stores and Rexall. As of December 31 2024 there were 693 HealthTab systems operating in Shoppers Drug Mart locations with 448 in Ontario 74 in British Columbia 12 in Nova Scotia 151 in Alberta 1 in Prince Edward Island 2 in Saskatchewan and 5 in New Brunswick. As of May 31 2025 the company had 14 HealthTab systems operating in Rexall stores including 9 in Ontario 4 in Alberta and 1 in Saskatchewan. The company also works with the Ontario Pharmacists Association which represents over 10,000 members and 4,600 community pharmacy locations to promote HealthTab adoption. In the United Kingdom Avricore launched its first HealthTab deployment in November 2024 in North East London and has partnered with Abbott Rapid Diagnostics UK Ireland to distribute Afinion 2 devices for diabetes and heart disease screening. The company’s expansion plans in the UK are supported by NHS funding commitments including £645 million in 2024 and £617 million in 2025 for pharmacy led services.